Synchroneuron's Series A Round

Synchroneuron raised a round of funding on February 06, 2012. Investors include Morningside Group (晨兴集团).

Synchroneuron is a biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders. Tardive dyskinesia (TD) is a chronic, usually irreversible an…

Articles about Synchroneuron's Series A Round: